These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29650803)

  • 1. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Winn A; Zarei P; O'Grady M; Huang ES
    Diabetes Care; 2018 Jun; 41(6):1227-1234. PubMed ID: 29650803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Zarei P; Winn AN; O'Grady M; Huang ES
    Med Decis Making; 2018 Nov; 38(8):942-953. PubMed ID: 30403576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
    Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid.
    Frank J; Son D; Szafranski K; Poon Y
    J Manag Care Spec Pharm; 2024 Sep; 30(9):917-928. PubMed ID: 39109990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran.
    Molaee MC; Naseri ZG; Karami MA
    Value Health Reg Issues; 2024 Sep; 43():101002. PubMed ID: 38820700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes.
    Huang ES; O'Grady M; Basu A; Winn A; John P; Lee J; Meltzer D; Kollman C; Laffel L; Tamborlane W; Weinzimer S; Wysocki T;
    Diabetes Care; 2010 Jun; 33(6):1269-74. PubMed ID: 20332354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting.
    Gardner D; Lakkad M; Qiu Z; Inoue Y; Rama Chandran S; Wherry K
    Diabetes Technol Ther; 2024 May; 26(5):324-334. PubMed ID: 38215206
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: Results From the DIAMOND Trial.
    Ruedy KJ; Parkin CG; Riddlesworth TD; Graham C;
    J Diabetes Sci Technol; 2017 Nov; 11(6):1138-1146. PubMed ID: 28449590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
    Del Prato S; Giorgino F; Szafranski K; Poon Y
    Diabetes Obes Metab; 2024 Sep; 26(9):3633-3641. PubMed ID: 38853717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
    Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
    Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
    Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
    Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial.
    Pratley RE; Kanapka LG; Rickels MR; Ahmann A; Aleppo G; Beck R; Bhargava A; Bode BW; Carlson A; Chaytor NS; Fox DS; Goland R; Hirsch IB; Kruger D; Kudva YC; Levy C; McGill JB; Peters A; Philipson L; Philis-Tsimikas A; Pop-Busui R; Shah VN; Thompson M; Vendrame F; Verdejo A; Weinstock RS; Young L; Miller KM;
    JAMA; 2020 Jun; 323(23):2397-2406. PubMed ID: 32543682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin.
    Kim JY; Ilham S; Alshannaq H; Pollock RF; Ahmed W; Norman GJ; Jin SM; Kim JH
    J Med Econ; 2024; 27(1):1245-1252. PubMed ID: 39275990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.